U.S. Omega 3 Encapsulation Market Size, Share & Forecast 2026–2032

ID: MR-11680 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Omega-3 Encapsulation Market
  • ✓Market Size 2024: USD 1.42 billion
  • ✓Market Size 2032: USD 2.34 billion
  • ✓CAGR: 6.6%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Tariff-Exposed Feedstock Dependence: Peruvian anchovy oil supplies much of U.S. fish oil feedstock, and the 10 percent reciprocal tariff under Executive Order 14257 raises softgel fillers' input costs. Cooke Inc.'s Omega Protein menhaden plant in Reedville, Virginia is the scaled domestic alternative.
FINDING 02
Prescription EPA Resists Substitution: Algal DHA from DSM-firmenich is widely expected to displace marine oil in U.S. softgels as vegan demand rises. The opposite is occurring: Amarin's Vascepa keeps fish-derived EPA concentrates in demand because pharmaceutical purity specifications favour them.
ANALYST RECOMMENDATION

Analyst Recommendation — Lock Feedstock Contracts Early: Procurement teams should secure multi-year marine oil supply agreements with Cooke Inc. and Peruvian processors before the fourth quarter of 2026 to fix landed costs. Encapsulators should also file GRAS notices for algal DHA ingredients by mid-2026 to preserve sourcing flexibility.

Omega-3 Encapsulation in the United States: Market Overview

The United States omega-3 encapsulation market converts EPA and DHA concentrates into softgels, hard capsules, and tablets for dietary supplements and prescription drugs. Valued at USD 1.42 billion in 2024, it is structured in three tiers: contract softgel manufacturers such as Catalent and Procaps, ingredient suppliers including BASF and DSM-Firmenich, and branded retailers such as Pharmavite's Nature Made line.

Policy shaped this structure more than consumer preference alone. The Dietary Supplement Health and Education Act of 1994 classified supplements as foods rather than drugs, which sustained a fragmented supplement sector. The FDA's dietary supplement current good manufacturing practice rule at 21 CFR Part 111 then pushed production toward certified encapsulators. Government dominance is concentrated in the prescription tier, where FDA approval and Medicare Part D set pricing, while private contract manufacturers have led supplement capacity expansion.

Policy-Driven Growth in US Omega-3 Encapsulation

The Inflation Reduction Act of 2022 (Public Law 117-169) capped Medicare Part D out-of-pocket spending at USD 2,000 per year from 2025. This reduces patient cost for prescription icosapent ethyl capsules such as Vascepa, expanding volume for pharmaceutical-grade softgel fillers. Higher prescription throughput translates directly into contracted encapsulation capacity, because branded EPA products require tightly specified fill and oxidation controls.

The FDA's qualified health claim for EPA and DHA and coronary heart disease, authorised in 2004, supports consumer labelling of omega-3 capsules. The Dietary Guidelines for Americans 2020–2025 recommend two seafood servings weekly, and many consumers fall short, creating supplement demand. Brands use these claims in packaging, which pulls volume into concentrated softgel formats that offer dose consistency and shelf stability.

Regulatory Barriers and Compliance Costs

FDA's Office of Dietary Supplement Programs enforces 21 CFR Part 111, requiring identity testing of every incoming ingredient, validated fill-weight controls, and documented batch records. Smaller encapsulators typically spend several hundred thousand dollars annually on quality systems and third-party audits to remain compliant. Delays arise when new ingredients need premarket review.

New dietary ingredients require a premarket notification to FDA under 21 U.S.C. 350b, which must be submitted at least 75 days before marketing. Under California Proposition 65, administered by the Office of Environmental Health Hazard Assessment, products containing trace contaminants trigger a 60-day notice period before enforcement suits can proceed. Feedstock supply is also constrained by the Atlantic menhaden quotas set by the Atlantic States Marine Fisheries Commission.

Policy-Created Opportunities in US Omega-3 Encapsulation

The Part D out-of-pocket cap creates the most immediate opportunity. Encapsulators with validated pharmaceutical-grade lines, including those certified to current good manufacturing practice for drugs under 21 CFR Parts 210 and 211, can supply generic or branded icosapent ethyl partners at volume. Contract capacity serving Medicare-covered patients will command higher utilisation through 2026.

FDA's planned overhaul of the generally recognised as safe pathway, directed by HHS in March 2025, removes self-affirmed GRAS notices. Algal DHA producers must then file formal notices, which favours encapsulators offering documented regulatory support. Domestic menhaden processing offers a second opportunity, as tariff exposure on Peruvian oil favours suppliers with Virginia-based feedstock.

Market at a Glance

MetricValue
Market Size 2024USD 1.42 billion
Market Size 2032USD 2.34 billion
Growth Rate (CAGR)6.6%
Most Critical Decision FactorFeedstock cost and tariff exposure on marine oil imports
Largest RegionWest Coast (California and Washington)
Competitive StructureFragmented supplement tier with concentrated contract manufacturing

Leading Market Participants

  • Catalent
  • Lonza
  • Procaps Group
  • BASF
  • DSM-Firmenich
  • Croda International
  • Cooke Inc.
  • Nordic Naturals
  • Pharmavite
  • Amarin

Regulatory and Policy Environment

The primary legislation is the Dietary Supplement Health and Education Act of 1994, which amended the Federal Food, Drug, and Cosmetic Act. FDA's Office of Dietary Supplement Programs administers it alongside the NIH Office of Dietary Supplements, while the Federal Trade Commission enforces advertising claims under Section 5 of the FTC Act. Compliance requires current good manufacturing practice under 21 CFR Part 111, substantiated structure-function claims, and adverse event reporting within 15 business days.

Upcoming changes include the GRAS reform proposed rule, which HHS directed FDA to pursue in 2025 to eliminate self-affirmed GRAS status. Compared with regional peers, the U.S. framework is lighter on premarket approval than Canada's Natural Health Products Regulations, which require a Health Canada product licence before sale. The European Union is stricter on claims under Regulation (EC) No 1924/2006, which requires authorisation of every health claim before use.

Long-Term Policy Outlook for Omega-3 Encapsulation in the US

By 2032, the GRAS reform will move most algal and novel omega-3 ingredients into formal notification, raising entry costs for small suppliers. Encapsulators with in-house regulatory affairs teams will gain share as ingredient qualification timelines lengthen. The Part D out-of-pocket cap, set at USD 2,000 for 2025, is indexed to annual Medicare parameters and will sustain prescription volume growth through the forecast period.

Fishery policy will reshape feedstock economics. ASMFC quota decisions on Atlantic menhaden will determine domestic crude oil availability, while tariff regimes on Peruvian and Chilean imports will set the import cost floor. Suppliers that secure multi-year domestic feedstock will hold margin advantage as these policies converge toward 2032.

Frequently Asked Questions

The FDA's Office of Dietary Supplement Programs enforces current good manufacturing practice under 21 CFR Part 111 for supplement encapsulators. Drug-grade prescription capsules fall under current good manufacturing practice for drugs in 21 CFR Parts 210 and 211.
A new dietary ingredient requires a premarket notification to FDA under 21 U.S.C. 350b at least 75 days before marketing. Ingredients qualifying as GRAS under current rules require no FDA notice if self-affirmed.
HHS directed FDA in 2025 to eliminate self-affirmed GRAS status, so algal DHA producers will need formal FDA notices. Suppliers without documented safety dossiers will face longer qualification timelines.
Yes, products containing listed contaminants such as lead or PCBs above safe-harbour levels require a warning under Proposition 65. Enforcement suits require a 60-day notice to the alleged violator.
The Inflation Reduction Act caps Medicare Part D out-of-pocket spending at USD 2,000 from 2025. This lowers patient cost for branded prescription EPA capsules such as Vascepa.

Market Segmentation

By Encapsulation Format
  • Softgel
  • Hard Capsule
  • Enteric-Coated Capsule
  • Microencapsulated Powder
By End Use
  • Dietary Supplements
  • Prescription Pharmaceuticals
  • Functional Foods and Beverages
  • Infant and Medical Nutrition
By Feedstock Source
  • Menhaden Fish Oil
  • Anchovy Oil
  • Krill Oil
  • Algal Oil

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Omega-3 Encapsulation - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Encapsulation Format Insights
4.1 Softgel
4.2 Hard Capsule
4.3 Enteric-Coated Capsule
4.4 Microencapsulated Powder
4.5 Others
Chapter 05 End Use Insights
5.1 Dietary Supplements
5.2 Prescription Pharmaceuticals
5.3 Functional Foods and Beverages
5.4 Infant and Medical Nutrition
5.5 Others
Chapter 06 Feedstock Source Insights
6.1 Menhaden Fish Oil
6.2 Anchovy Oil
6.3 Krill Oil
6.4 Algal Oil
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Catalent
7.2.2 Lonza
7.2.3 Procaps Group
7.2.4 BASF
7.2.5 DSM-Firmenich
7.2.6 Croda International
7.2.7 Cooke Inc.
7.2.8 Nordic Naturals
7.2.9 Pharmavite
7.2.10 Amarin
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.